CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?
CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immun...
Saved in:
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/12/1/e001157.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|